Frequently Asked Questions

BPC-157 is a synthetic peptide fragment derived from body protection compound (BPC), a protein originally isolated from human gastric juice, and has been studied extensively in preclinical models since the 1990s.

No. BPC-157 is a synthesized 15-amino-acid fragment designed to be more stable than the full parent protein for research purposes.

The 'no DAC' variant lacks the Drug Affinity Complex modification that extends plasma half-life via albumin binding. It is a shorter-acting GHRH(1-29) analog, commonly referred to as Mod GRF 1-29 in the research literature.

In research models, it is studied as a GHRH receptor agonist, meaning its research-observed effects on growth hormone secretion are mediated through pituitary GHRH receptors rather than direct hormone replacement.

Yes. GHK is a naturally occurring human tripeptide first isolated from plasma; it has a high affinity for copper(II) ions and is typically supplied and studied in its copper-complexed form, GHK-Cu.

GHK has a very high binding affinity for Cu(II). Research indicates the copper-complexed form is central to GHK's studied biological activity, particularly in extracellular matrix remodeling research.

Research literature describes Ipamorelin as a highly selective ghrelin receptor (GHS-R1a) agonist, with studies reporting minimal off-target effects on cortisol, aldosterone, and prolactin secretion compared to earlier-generation secretagogues like GHRP-6.

No. Ipamorelin is a growth hormone secretagogue — it is studied for its ability to stimulate endogenous GH release via the ghrelin receptor, rather than supplying exogenous growth hormone.

MOTS-c is encoded within a short open reading frame in the mitochondrial 12S ribosomal RNA gene, distinguishing it from peptides encoded by nuclear DNA. It is one of several identified 'mitochondrial-derived peptides.'

As a more recently characterized research peptide, MOTS-c does not yet have a formally assigned CAS registry number in common use; batch identity is confirmed via HPLC and mass spectrometry.

No. NAD+ is a dinucleotide coenzyme, not a peptide, but it is included in Peptide Factory's catalog given its central role in the metabolic and longevity research programs shared by many of our peptide clients.

NAD+ is chemically labile and susceptible to hydrolysis and degradation from heat, light, moisture, and repeated freeze-thaw cycles, which is why we recommend minimizing reconstituted storage time relative to more stable peptides.

Retatrutide is engineered to activate three distinct incretin/glucagon-family receptors — GIP, GLP-1, and glucagon receptors — simultaneously, distinguishing it from single- or dual-receptor incretin research compounds.

No. As of this writing, Retatrutide remains an investigational compound studied in clinical trials for metabolic research. Peptide Factory supplies it exclusively as a research-grade compound for laboratory and analytical use.

No. Selank is a synthetic analog derived from tuftsin's structure, with an added Pro-Gly-Pro sequence extension developed by Russian researchers to improve enzymatic stability relative to the parent peptide.

Standard bulk lots are supplied at ≥99% purity by HPLC, with a certificate of analysis available on request for each batch.

Semax is a synthetic heptapeptide derived from fragment 4-10 of adrenocorticotropic hormone (ACTH), with the native C-terminal sequence modified for improved metabolic stability.

No. The structural modifications made to the ACTH(4-10) fragment were specifically designed to eliminate hormonal activity while preserving the neuroactive properties studied in the research literature.

TB-500 is the common research name used for synthetic peptide preparations corresponding to Thymosin Beta-4, a naturally occurring 43-amino-acid protein involved in actin regulation and cell migration.

Research has focused on its role in actin sequestration, cell migration, and angiogenesis in preclinical wound-healing and cardiac tissue models.

Tesamorelin is the full 44-amino-acid GHRH sequence with an N-terminal trans-3-hexenoyl modification for stability, whereas CJC-1295 (no DAC) is a 29-amino-acid truncated analog. Both are studied as GHRH receptor agonists but differ in structure and research history.

A tesamorelin-based product has received regulatory approval in some jurisdictions for a specific indication. Peptide Factory supplies Tesamorelin exclusively as a research-grade compound for laboratory use — not as a clinical or consumer product.